AlphaQuest LLC Has $1.59 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AlphaQuest LLC raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.3% during the fourth quarter, HoldingsChannel reports. The firm owned 2,236 shares of the biopharmaceutical company’s stock after acquiring an additional 262 shares during the quarter. AlphaQuest LLC’s holdings in Regeneron Pharmaceuticals were worth $1,593,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Rakuten Securities Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares in the last quarter. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $26,000. Truvestments Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $39,000. OFI Invest Asset Management acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $28,000. Finally, Valley Wealth Managers Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $49,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $707.51 on Friday. The stock has a 50-day moving average price of $696.12 and a 200-day moving average price of $851.05. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market cap of $77.35 billion, a PE ratio of 18.48, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the company posted $11.86 EPS. The business’s quarterly revenue was up 10.3% on a year-over-year basis. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on REGN. TD Cowen reduced their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Bank of America reiterated an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Finally, Truist Financial dropped their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.